Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.

Abstract

BACKGROUND:

An estimated 7% of patients with asthma have chronic rhinosinusitis with nasal polyps (CRSwNP), and more than 80% have at least some radiographic evidence of sinonasal inflammation. Aspirin sensitivity is strongly associated with elevated blood eosinophil levels and increased asthma severity. Intravenous (IV) reslizumab has been shown to improve asthma control in patients with nasal polyps.

OBJECTIVE:

These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity.

METHODS:

Patients aged 12-75 years with elevated blood eosinophils (≥400 cells/μL) and inadequately controlled asthma were randomized to receive placebo or reslizumab (3 mg/kg IV) every 4 weeks for 52 weeks. Patients continued their background asthma maintenance therapy during the study. Information regarding the presence of CRSwNP was obtained through patient-reported medical history.

RESULTS:

Add-on reslizumab treatment reduced the frequency of clinical asthma exacerbations by 83% versus placebo among patients with CRSwNP. Among patients with and without aspirin sensitivity, reductions of 79% and 84%, respectively, were observed. Patients with CRSwNP (with and without aspirin sensitivity) treated with reslizumab add-on therapy also had significant improvements in lung function, as measured by forced expiratory volume in 1 second, compared with placebo. Among patients with CRSwNP, reslizumab was also associated with improvements in patient-reported asthma control and asthma quality of life.

CONCLUSIONS:

Patients with eosinophilic asthma and self-reported CRSwNP, with and without aspirin sensitivity, are highly responsive to treatment with reslizumab for asthma-related outcomes. These findings suggest that prospective investigation of reslizumab in this patient population is warranted.

• Authors: Steven F Weinstein, Rohit K Katial, Philip Bardin, Stephanie Korn, Mirna McDonald, Margaret Garin, Eric D Bateman, Flavia C L Hoyte, Matthew Germinaro
• Journal: The journal of allergy and clinical immunology. In practice (J Allergy Clin Immunol Pract) Vol. 7 Issue 2 Pg. 589-596.e3 (02 2019) ISSN: 2213-2201 [Electronic] United States
• PMID: 30193936 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anti-Asthmatic Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal, Humanized
• reslizumab
• Aspirin

Topics

• Adolescent
• Adult
• Aged
• Anti-Asthmatic Agents (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Aspirin
• Asthma (drug therapy, epidemiology, immunology)
• Child
• Chronic Disease
• Comorbidity
• Eosinophils (immunology)
• Female
• Humans
• Male
• Middle Aged
• Nasal Polyps (drug therapy, epidemiology, immunology)
• Pulmonary Eosinophilia (drug therapy, epidemiology, immunology)
• Rhinitis (drug therapy, epidemiology, immunology)
• Self Report
• Sinusitis (drug therapy, epidemiology, immunology)
• Treatment Outcome
• Young Adult